American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition, Revised: DSM-IV-R. Washington, DC: American Psychiatric Association, 2000.
2.
DerogatisLR, KomerL, KatzM, et al.Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the VIOLET Study. J Sex Med, 2012; 9:1074–1085.
3.
ThorpJ, SimonJ, DattaniD, et al.Treatment of hypoactive sexual desire disorder in premenopausal women: Efficacy of flibanserin in the DAISY study. J Sex Med, 2012; 9:793–804.
4.
KatzM, DeRogatisLR, AckermanR, et al.Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial. J Sex Med, 2013; 10:1807–1815.
5.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause, 2013; 20:888–902; quiz 903–884.
6.
KingsbergSA, WysockiS, MagnusL, KrychmanML. Vulvar and vaginal atrophy in postmenopausal women: Findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med, 2013; 10:1790–1799.
7.
PortmanDJ, LabrieF, ArcherDF, et al.Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause, 2015; 22:1289–1295.
8.
US Food and Drug Administration letter to Paolo Peruzzi 2014. Available at www.accessdata.fda.gov/cdrh_docs/pdf13/K133895.pdf (accessed on January25, 2016).
9.
KrychmanM, ShifrenJL, LiuJH, KingsbergS, UtianWH. Menopause e-Consult. The North American Menopause Society (NAMS), 2015; 11:1–4.
10.
SalvatoreS, NappiRE, ZerbinatiN, et al.A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: A pilot study. Climacteric, 2014; 17:363–369.
